[The changes in the pharmacotherapy of heart failure with reduced ejection fraction and its effect on prognosis: experience in the Hungarian clinical practice].

MLA

Muk, Balázs, et al. “[The Changes in the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction and Its Effect on Prognosis: Experience in the Hungarian Clinical Practice].” Orvosi Hetilap, vol. 165, no. 18, May 2024, pp. 698–710. EBSCOhost, https://doi.org/10.1556/650.2024.33045.

APA

Muk, B., Pilecky, D., Bánfi-Bacsárdi, F., Füzesi, T., Gergely, G. T., Komáromi, A., Papp, E., Szőnyi, M. D., Forrai, Z., Kazay, Á., Solymossi, B., Vámos, M., Andréka, P., Piróth, Z., & Nyolczas, N. (2024). [The changes in the pharmacotherapy of heart failure with reduced ejection fraction and its effect on prognosis: experience in the Hungarian clinical practice]. Orvosi Hetilap, 165(18), 698–710. https://doi.org/10.1556/650.2024.33045

Chicago

Muk, Balázs, Dávid Pilecky, Fanni Bánfi-Bacsárdi, Tamás Füzesi, G Tamás Gergely, Anna Komáromi, Emese Papp, et al. 2024. “[The Changes in the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction and Its Effect on Prognosis: Experience in the Hungarian Clinical Practice].” Orvosi Hetilap 165 (18): 698–710. doi:10.1556/650.2024.33045.